Page 56 - CPG endometrial cancer
P. 56
5. Shiovitz S, Korde LA. Genetics of breast ผศ.พญ.นภา ปรญิ ญานติ กิ ลู
cancer: a topic in evolution. Ann Oncol 2015;
26(7):1291–1299. Survival in Triple-Negative Breast Cancer: Secondary
6. Piffer A, Luporsi E, Mathelin C (2018). Analysis of the GeparSixto Randomized Clinical
PALB2, a major susceptibility gene for breast Trial. JAMA Oncol (2017) 3:1378.
cancer. GynecolObstetFertilSenol 2018; 46(10–11): 12. Loibl S, O’Shaughnessy J, Untch M, Sikov
701–705. WM, Rugo HS, McKee MD, et al. Addition of
7. Lee, J. M., Ledermann, J. A. & Kohn, E. C. the PARP inhibitor veliparib plus carboplatin
PARP inhibitors for BRCA1/2 mutation or carboplatin alone to standard neoadjuvant
associated and BRCA-like malignancies. Ann. chemotherapy in triple-negative breast cancer
Oncol. 25, 32–40 (2014). (BrighTNess): a randomised, phase 3 trial.
8. Ashworth, A. A synthetic lethal therapeutic Lancet Oncol (2018) 19:497–509.
approach: poly(ADP) ribose polymerase 13. Sikov WM, Berry DA, Perou CM, Singh B,
inhibitors for the treatment of cancers Cirrincione CT, Tolaney SM, et al. Impact of
deficient in DNA double-strand break repair. J. the addition of carboplatin and/or bevacizumab
Clin. Oncol. 26, 3785–3790 (2008). to neoadjuvant once-per-week paclitaxel
9. Bhattacharyya, A., Ear, U. S., Koller, B. H., followed by dose-dense doxorubicin and
Weichselbaum, R. R. & Bishop, D. K. The cyclophosphamide on pathologic complete
breast cancer susceptibility gene BRCA1 is response rates in stage II to III triple-negative
required for subnuclear assembly of Rad51 breast cancer: CALGB 40603 (Alliance). J Clin
and survival following treatment with the Oncol Off J Am Soc Clin Oncol (2015) 33:13–21.
DNA cross-linking agent cisplatin. J. Biol. 14. Tutt ANJ, Garber JE, Kaufman B, Viale G,
Chem. 275, 23899–23903 (2000). Fumagalli D, et al. Adjuvant Olaparib for
10. NCCN guideline: Genetic/Familial High Patients withBRCA1- or BRCA2- Mutated
Risk Assessment Breast, Ovarian and Breast Cancer. N Engl J Med 2021; 384: 2394-
Pancreatic; version2.2022 March 9, 2022 2405.
(https://www.nccn.org/guidelines/guidelines- 15. Kilburn, L. S., TNT Trial Management Group.
detail?category= 2&id=1503) ‘Triple negative’ breast cancer: a new area
11. Hahnen E, Lederer B, Hauke J, Loibl S, for phase III breast cancer clinical trials. Clin.
Kr?ber S, et al. Germline Mutation Status, Oncol. 20, 35–39 (2008).
Pathological Complete Response, and Disease-Free 16. Byrski, T, Dent R, Blecharz P, Foszczynska-
Kloda M, Gronwald J. &Huzarski, T. et al. Results
of a phase II open-label,non- randomized trial of
47
